Supplemental Figure 1. Substitution of  $Hnf1\beta$ -CreER<sup>T2</sup> in Pulse-Chase Analyses with Sox9-CreER<sup>T2</sup> Confirms that Notch-Dependent TrPC Allocation Closes by E13. (A,B) Tamoxifen (Tam) administration to experimental mice induces Sox9-CreER<sup>T2</sup>-mediated expression of a dnMaml1-GFP fusion protein from the Rosa26 locus, rendering Sox9<sup>+</sup> TrPC-biased MPCs and their progeny permanently Notch-insensitive and GFP-labeled (A) while in control embryos, the same cell population is YFP-labeled but remains Notch signaling-intact following tamoxifen-induced Sox9-*CreER*<sup>T2</sup>-mediated recombination of the *Rosa26*<sup>YFP</sup> reporter (**B**). (**C**) Approximate temporal windows of Tam activity resulting from single intraperitoneal (i.p.) injections at E11.5, E12.5 or E13.5: pancreata were analysed at E15.5 whereupon cell fate of labeled TrPCs and their progeny was assessed on the basis of marker expression (**D**). *Sox9-CreER*<sup>T2</sup>-mediated recombination efficiency for both *Rosa26<sup>dnMaml1-eGFP</sup>* and *Rosa26<sup>YFP</sup>* alleles is of an order of magnitude greater than that achieved with Hnf1 $\beta$ -CreER<sup>T2</sup> (E-P). Qualitatively, cell fate distributions of control YFP<sup>+</sup> cells in E15.5 Sox9-CreER<sup>T2</sup>; Rosa26<sup>YFP</sup> and Notch-insensitive dnMaml1-GFP<sup>+</sup> cells in Sox9-CreER<sup>T2</sup>; Rosa26<sup>dnMaml1-eGFP</sup> pancreata following E11.5, E12.5 or E13.5 Tam i.p. mirror those seen using  $Hnf1\beta$ -CreER<sup>T2</sup>. While after an E11.5 Tam i.p., YFP<sup>+</sup> cells in control Sox9-CreER<sup>T2</sup>; Rosa26<sup>YFP</sup> pancreata can be found to express markers of all three compartments (E,G), by an E13.5 Tam i.p., YFP<sup>+</sup> cells are predominantly Sox9<sup>+</sup> or endocrine (Ngn3<sup>+</sup> or ChrA<sup>+</sup>) (**I,K,M,O**). Following Tam i.p. at E11.5, dnMaml1-GFP<sup>+</sup> cells in *Sox9-CreER<sup>T2</sup>; Rosa26<sup>dnMam/1-GFP</sup>* pancreata are predominantly Sox9<sup>-</sup> Ptf1a<sup>+</sup> with a proportion expressing endocrine markers (Ngn3, Chr-A) (F,H). Tam i.p at E12.5 or E13.5 similarly results in the vast majority of dnMaml1-GFP<sup>+</sup> cells being Sox9<sup>-</sup> although in contrast to the principally acinar labeling following E11.5 Tam i.p., dnMaml1-GFP<sup>+</sup> cells following E12.5 or E13.5 Tam i.p. are predominantly endocrine (Chr-A<sup>+</sup>) with a smaller proportion expressing Ptf1a (J,L,N,P). Scale bar = 50 µm.

**Supplemental Figure 2. Validation of Specificity of Anti-Dll1, -Jag1 and -Hes1 Antisera.** Rabbit monoclonal anti-Jag1 antibody (Cell Signaling Technology: 2620) gives membraneous signal on cells in the neural tube and weaker but specific membraneous staining throughout both pancreatic buds in E10.5 control mice (A,A'') but not  $Jag1^{-/-}$  littermates (B,B''). Similarly, goat anti-Jag1 antibody (Santa Cruz Biotechnology: sc-6011) gives membraneous signal on cells in the neural tube and weaker but specific membraneous signal on cells in the neural tube and weaker but specific membraneous signal on cells in the neural tube and weaker but specific membraneous signal on cells in the neural tube and weaker but specific membraneous staining throughout both pancreatic buds in E10.5 control

1

embryos (**C**,**C**") but not  $Jag1^{-/-}$  littermates (**D**,**D**"). Note that adjacent sections are shown in **A**-**D**": Jag1 is detected in the same cell populations using both antisera although the goat antibody yields stronger signal. Sheep anti-Dll1 antibody (R&D Systems: AF3970) yields heterogeneous membraneous signal on cells in the neural tube (nt), and weaker but specific signal in dorsal (dp) and ventral (vp) pancreas in E10.5 control embryos (**E**,**E**"), but not nullizygous  $Dl/l^{lacZ/lacZ}$  littermates (**F**,**F**"). Rabbit monoclonal anti-Hes1 antibody (Cell Signaling Technology: 11988) yields strong nuclear Hes1 signal in the neural tube and floorplate (fp) and throughout both pancreatic buds in E10.25 control embryos (**G**,**G**") but not  $Hes1^{-/-}$  littermates (**H**,**H**"). Sox9 signal is shown for reference. Pancreatic buds are demarcated by white dashed lines in **A**",**B**",**C**",**D**",**E**",**F**",**G**",**H**". Images of Sox9, ligand or Hes1 signal within each antibody combination were captured at the same exposure and processed equivalently except for inset panels for Dll1 (**E**",**F**") or Jag1 (**A**",**B**") in which weaker signal in pancreatic buds compared to neural tube is enhanced to show pancreas-specific signal (parallel enhancement performed for control and nullizygous images). duo, duodenum; cbd, common bile duct. Scale bar = 50 µm.

**Supplemental Figure 3. Cell-Specific Expression of Jag1 and Dll1 in the Developing Pancreas.** Sections of an E15.5 *Jag1*<sup>J1VmC</sup> embryo stained for Venus (Jag1-Venus) and Sox9 (**A**) or mCherry (Jag1-mCherry), GFP (from Hes1-eGFP) and Sox9 (**C**) and sections of an E15.5 (or E12.5, **E**) *Dll1*<sup>D1VmC</sup> embryo stained for Venus (Dll1-Venus) and Sox9 (**B**) or mCherry (Dll1-mCherry) and Sox9 with either GFP (Hes1-eGFP) (**D**) or Jag1 (**E**,**F**). Sections of E12.5 (**G-I**) or E15.5 (**J-L**) pancreata stained for Jag1, Pecam and E-Cadherin (**G**,**J**), Jag1, Ngn3 and glucagon with insulin (**H**,**K**) or Jag1, Ptf1a, and Sox9 (**I**,**L**). Sections of E12.5 (**M-O**) or E15.5 (**P-R**) pancreata stained for Dll1, Pecam and E-Cadherin (**M**,**P**), Dll1, Ngn3 and glucagon with insulin (**N**,**Q**) or Dll1, Ptf1a, and Sox9 (**O**,**R**).

#### **Supplemental Figure 4. PD Patterning is Perturbed Following Mosaic Endodermal Deletion of Jag1 and Dll1. (A-D')** IF on sections of E12.5 embryos of the indicated genotypes for Ptf1a, Nkx6.1, YFP and E-Cadherin. (E-G) Scatter plots showing quantifications of the number of Ptf1a<sup>+</sup> (Ptf1a<sup>+</sup> Nkx6.1<sup>-</sup>) TiPCs (E), Nkx6.1<sup>+</sup> (Ptf1a<sup>-</sup> Nkx6.1<sup>+</sup>) TrPCs (F) and Ptf1a<sup>+</sup> Nkx6.1<sup>+</sup> cells (G) relative to the number of


progenitor cells (the total number of Ptf1a<sup>+</sup> and/or Nkx6.1<sup>+</sup> cells) in dorsal pancreata. Data are

presented as mean  $\pm$  S.E.M. *P*-values are indicated on the plots. Genotypes are abbreviated in scatter plots by the first letter (D = DII or J = Jag) of the ligand gene(s) deleted by *Sox17*<sup>CreERT2</sup>.


Supplemental Figure 5. Resolution of PD Patterning is Delayed by Two Days in the Jag1<sup> $\Delta$ Foxa2</sup> Pancreas. IF for Ptf1a and either Nkx6.1 (A,B,G,H) or Sox9 (C,D,I,J) shows that while Ptf1a expression is maintained proximally in the Jag1<sup> $\Delta$ Foxa2</sup> pancreas at E13.5 (B,D) compared to controls (A,C), Ptf1a and Nkx6.1 expression domains have resolved by E14.5 in the mutant with loss of the distal-most Nkx6.1<sup>+</sup> (H, inset) and Sox9<sup>+</sup> (J, inset) TrPC-derived duct cells. Presence of insulin<sup>+</sup>  $\beta$ -cells and Ngn3<sup>+</sup> endocrine precursors is ostensibly unaffected in E13.5 (F) or E14.5 (L) Jag1<sup> $\Delta$ Foxa2</sup> pancreata relative to control E13.5 (E) or E14.5 (K) littermates.


Supplemental Figure 6. Apicobasal Polarity is Retained in E15.5  $Jag1^{\Delta Foxa2}$  Acini But Lost Prior to Birth. IF for ZO-1 shows it to be maintained apically on Ptf1a<sup>+</sup> acinar and Sox9<sup>+</sup> duct cells in the E15.5  $Jag1^{\Delta Foxa2}$  (B-C') as control (A,A') pancreas. Similarly, IF for PKC $\zeta$  demonstrates it to be maintained apically on Ptf1a<sup>+</sup> acinar and Pdx1<sup>Lo</sup> duct cells in the E15.5  $Jag1^{\Delta Foxa2}$  (E-F') as control (D,D') pancreas. At E18.5 however, while apical ZO-1 is still expressed on Ptf1a<sup>+</sup> CPA1<sup>+</sup> acinar cells (as well as duct cells) in control mice (G-G'), it is downregulated in epithelial ((R26)YFP<sup>+</sup>) Ptf1a<sup>+</sup> CPA1<sup>+</sup> "ring"-like structures (asterisks) in the  $Jag1^{\Delta Foxa2}$  pancreas (H-I'). Likewise, PKC $\zeta$ , expressed apically on Ptf1a<sup>+</sup> CPA1<sup>+</sup> acinar cells (and duct cells) in the E18.5 control pancreas (J,J') is depleted in Ptf1a<sup>+</sup> CPA1<sup>+</sup> ringlike structures (asterisks) in the  $Jag1^{\Delta Foxa2}$  pancreas (K-L').

Supplemental Figure 7. Endocrine Paucity and Acinar Dysmorphogenesis are Exacerbated with Development. IF for insulin, glucagon and somatostatin shows a greater extent of loss of the laterarising somatostatin<sup>+</sup>  $\delta$ -cells than of either insulin<sup>+</sup>  $\beta$ -cells or glucagon<sup>+</sup>  $\alpha$ -cells in the E18.5 *Jag1*<sup> $\Delta$ Foxa2</sup> pancreas (**B**) compared with control littermates (**A**). Expression of the acinar markers amylase and CPA1 is retained in acinar cells of E18.5 *Jag1*<sup> $\Delta$ Foxa2</sup> (**D**) as in control (**C**) pancreas, including dilated "ring"-like structures although their expression is aberrantly basal (**D**, inset). IF for Muc1 and the ductal markers Cytokeratin 19 (CK19) and DBA reveals discontinuous, dispersed ductal structures in the E18.5 *Jag1*<sup> $\Delta$ Foxa2</sup> pancreas (**F**) in contrast to the extensive, continuous ductal tree of control littermates (**E**). The amylase<sup>+</sup> CPA1<sup>+</sup> ring-like structures also express CK19 (ring-like structure in insets on **D** and **F** from the same region of adjacent sections). Insets are displayed with and without the YFP channel to demarcate epithelium for clarity.



Supplemental Figure 2





Jag1/\*ccm/E-Cadherin
Jag1/%cm\*/Glucagon & Insulin
Jag1/\*c1\*/Sox9

Image: Strate Strate

